Latest news
Otsuka's VOYXACT hits VISIONARY two-year eGFR goal in IgA nephropathy - DealroomDealroom · Wed, 05 Aug 2026 04:43:21 GMTOtsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial - Clinical Trials ArenaClinical Trials Arena · Tue, 04 Aug 2026 14:31:49 GMTOtsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy - Business WireBusiness Wire · Mon, 03 Aug 2026 21:00:00 GMTDaingerfield’s + Peppervine August 7, 2026 – Two Celebrated Resturants, Two Visionary Chefs, One Exclusive Three-Course Dining Experience - High Country PressHigh Country Press · Sat, 01 Aug 2026 09:20:17 GMT